Food, Drugs, Healthcare, Life Sciences

The upcoming UK general election on 4 July 2024 represents a pivotal moment for the healthcare and life sciences sectors. Stakeholders in the Life Sciences sector have been looking for policies that could address the impact of Brexit and provide a regulatory landscape to encourage innovation, in particular in the area of the use of artificial intelligence (AI) in medical technologies.

The NHS is now offering an injectable form of Keytruda (pembrolizumab) that can be administered in under two minutes, dramatically reducing treatment times from over an hour. This advancement, following last year's introduction of injectable nivolumab, promises to save hundreds of thousands of hours annually while cutting costs and improving patient care across cancer treatment services.

The growing use of combination therapies pairing small molecules with biologics is reshaping drug development, delivering clinically meaningful synergy and improved efficacy. However, as the science advances, so do the intellectual property and regulatory challenges, particularly where multiple stakeholders are involved in bringing these therapies to market.

Donna Ockenden's final report into maternity services at Nottingham University Hospitals NHS Trust examines over 2,500 cases from 2012 to 2025, representing the largest single review of its kind in NHS history. The report identifies recurring failures in listening to women, clinical escalation, staffing, training and governance, while making 18 Immediate and Essential Actions for implementation across England's maternity services.

The upcoming UK general election on 4 July 2024 represents a pivotal moment for the healthcare and life sciences sectors. Stakeholders in the Life Sciences sector have been looking for policies that could address the impact of Brexit and provide a regulatory landscape to encourage innovation, in particular in the area of the use of artificial intelligence (AI) in medical technologies.

The NHS is now offering an injectable form of Keytruda (pembrolizumab) that can be administered in under two minutes, dramatically reducing treatment times from over an hour. This advancement, following last year's introduction of injectable nivolumab, promises to save hundreds of thousands of hours annually while cutting costs and improving patient care across cancer treatment services.

The NHS is now offering an injectable form of Keytruda (pembrolizumab) that can be administered in under two minutes, dramatically reducing treatment times from over an hour. This advancement, following last year's introduction of injectable nivolumab, promises to save hundreds of thousands of hours annually while cutting costs and improving patient care across cancer treatment services.

The growing use of combination therapies pairing small molecules with biologics is reshaping drug development, delivering clinically meaningful synergy and improved efficacy. However, as the science advances, so do the intellectual property and regulatory challenges, particularly where multiple stakeholders are involved in bringing these therapies to market.

Following widespread litigation over Halozyme's SPC families for Herceptin Hylecta and MabThera, Europe's highest court received a critical referral addressing whether recombinant human hyaluronidase can be considered an "active ingredient" despite its classification as an excipient in marketing authorisation documents. Advocate General Emiliou has now published a significant legal opinion proposing that substances expressly designated as excipients cannot be regarded as active ingredients for SPC purposes.